Salta al contenuto principale
Ricerc@Sapienza
Toggle navigation
Home
Login
Home
Persone
daniela.melchiorri@uniroma1.it
Daniela Melchiorri
Professore Ordinario
Struttura:
DIPARTIMENTO DI FISIOLOGIA E FARMACOLOGIA "VITTORIO ERSPAMER"
E-mail:
daniela.melchiorri@uniroma1.it
Pagina istituzionale corsi di laurea
Curriculum Sapienza
Pubblicazioni
Titolo
Pubblicato in
Anno
Tracking neuroinflammatory biomarkers in Alzheimer's disease: a strategy for individualized therapeutic approaches?
JOURNAL OF NEUROINFLAMMATION
2024
Multi-year analysis of the global preclinical antibacterial pipeline: trends and gaps
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
2024
Addressing urgent priorities in antibiotic development: insights from WHO 2023 antibacterial clinical pipeline analyses
THE LANCET MICROBE
2024
Alzheimer's disease and neuroinflammation: will new drugs in clinical trials pave the way to a multi-target therapy?
FRONTIERS IN PHARMACOLOGY
2023
Editorial: Pharmacology of autoimmune and neuroinflammatory disease from a preclinical and clinical perspective
2023
The European Medicines Agency review of entrectinib for the treatment of adult or paediatric patients with solid tumours who have a neurotrophic tyrosine receptor kinase gene fusions and adult patients with non-small-cell lung cancer harbouring ROS1 rearrangements
ESMO OPEN
2021
Combinations in the first-line treatment of patients with advanced/metastatic renal cell cancer: Regulatory aspects
ESMO OPEN
2020
Blinatumomab for Acute Lymphoblastic Leukemia: The First Bispecific T-Cell Engager Antibody to Be Approved by the EMA for Minimal Residual Disease
THE ONCOLOGIST
2020
Revocation of the conditional marketing authorisation of a cancer medicine: the olaratumab experience
EUROPEAN JOURNAL OF CANCER
2019
European Medicines Agency review of ixazomib (Ninlaro) for the treatment of adult patients with multiple myeloma who have received at least one prior therapy
ESMO OPEN
2019
Optimising bench science to withstand regulatory scrutiny
PHARMACOLOGICAL RESEARCH
2019
Targeting metabotropic glutamate receptors in the treatment of primary brain tumors
CURRENT OPINION IN PHARMACOLOGY
2018
Targeting metabotropic glutamate receptors in the treatment of primary brain tumors
CURRENT OPINION IN PHARMACOLOGY
2018
European medicines agency approval summary: zaltrap for the treatment of patients with oxaliplatin-resistant metastatic colorectal cancer
ESMO OPEN
2017
Implementing quality by design for biotech products: are regulators on track?
MABS
2015
Gruppi di ricerca - Responsabile
Monitoraggio e valutazione comparativa dei farmaci
Il processo di autorizzazione dei farmaci in Europa e il suo impatto sull'approvazione dei farmaci
© Università degli Studi di Roma "La Sapienza" - Piazzale Aldo Moro 5, 00185 Roma